A Phase 1, Open-label, Single-center Study to Investigate the Pharmacokinetics and Metabolism of GLPG1690 in Healthy Male Subjects Following Single Intravenous GLPG1690 Microtracer and Oral [14C]-GLPG1690 Administrations
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Ziritaxestat (Primary) ; Ziritaxestat (Primary)
- Indications Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Galapagos NV
- 11 Feb 2019 Status changed from recruiting to completed.
- 03 Jan 2019 New trial record